Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Yes
- 1 June 2020
- journal article
- editorial
- Published by Elsevier BV in Revue Neurologique
- Vol. 176 (6), 497-499
- https://doi.org/10.1016/j.neurol.2020.03.003
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Clinical course of multiple sclerosis: A nationwide cohort studyMultiple Sclerosis Journal, 2016
- Importance of early treatment initiation in the clinical course of multiple sclerosisMultiple Sclerosis Journal, 2016
- Long‐term evolution of multiple sclerosis disability in the treatment eraAnnals of Neurology, 2016
- Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysisMultiple Sclerosis and Related Disorders, 2016
- Can we measure long-term treatment effects in multiple sclerosis?Nature Reviews Neurology, 2014
- Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme resultsJournal of Neurology, Neurosurgery & Psychiatry, 2014
- Evidence for a two-stage disability progression in multiple sclerosisBrain, 2010
- Disability progression in multiple sclerosis is slower than previously reportedNeurology, 2006
- Relapses and Progression of Disability in Multiple SclerosisThe New England Journal of Medicine, 2000
- THE NATURAL HISTORY OF MULTIPLE SCLEROSIS: A GEOGRAPHICALLY BASED STUDYBrain, 1989